• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病患者的胃肠道肿瘤:加强预防策略的机遇

Gastrointestinal neoplasia in patients with inflammatory bowel disease: Opportunities to enhance preventative strategies.

作者信息

Young Edward, Lawrence Matthew, Thomas Michelle, Andrews Jane

机构信息

Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, IBD Service Royal Adelaide Hospital Adelaide South Australia Australia.

Colorectal Surgery Unit Royal Adelaide Hospital Adelaide South Australia Australia.

出版信息

JGH Open. 2019 May 14;3(6):513-517. doi: 10.1002/jgh3.12193. eCollection 2019 Dec.

DOI:10.1002/jgh3.12193
PMID:31832552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6891013/
Abstract

BACKGROUND AND AIMS

Gastrointestinal (GI) adenocarcinoma, especially colorectal cancer (CRC), is a devastating complication of inflammatory bowel disease (IBD). We sought to examine the role of chronic inflammation and other possible predictors of the development of CRC, as well as assess as yet unexamined factors such as psychological comorbidity and engagement in care.

METHODS

This study included all patients involved in a tertiary hospital IBD service diagnosed with CRC between 2007 and 2017. Reports from histological specimens were assessed, and all those with adenocarcinoma, high-grade dysplasia (HGD), or multifocal low-grade dysplasia (LGD) originating within IBD-affected mucosa were included in the study.

RESULTS

A total of 32 patients were included in the study (17 with adenocarcinoma and 15 with HGD/multifocal LGD). The majority had a duration of disease >20 years. Eleven patients (34%, CI 20-52%) had previous disease-related surgery, and 16 (50%, CI 34-66%) had multiple previous disease-related admissions. Thirteen patients (62%, CI 41-79%) had >50% of CRP results higher than 8 mg/L. Psychiatric comorbidities were common, with 19 patients (59%, CI 42-74%) having a psychiatric comorbidity or poor engagement in treatment.

CONCLUSION

In this cohort, we have highlighted poor engagement, hesitation to up-titrate therapy when indicated, and psychological comorbidities as likely contributors to poor disease control and development of GI adenocarcinoma. Based on our data, these easily identifiable clinical care factors should not be overlooked when addressing IBD-related GI malignancy prevention. Additional research is required to assess a direct causal relationship, but this study would support the incorporation of psychology services into IBD clinics.

摘要

背景与目的

胃肠道腺癌,尤其是结直肠癌(CRC),是炎症性肠病(IBD)的一种严重并发症。我们试图研究慢性炎症在CRC发生中的作用以及其他可能的预测因素,并评估尚未研究的因素,如心理合并症和治疗参与度。

方法

本研究纳入了2007年至2017年间在一家三级医院IBD服务中心被诊断为CRC的所有患者。对组织学标本报告进行评估,所有起源于IBD受累黏膜的腺癌、高级别异型增生(HGD)或多灶性低级别异型增生(LGD)患者均纳入研究。

结果

本研究共纳入32例患者(17例腺癌患者和15例HGD/多灶性LGD患者)。大多数患者病程>20年。11例患者(34%,可信区间20 - 52%)曾接受与疾病相关的手术,16例患者(50%,可信区间34 - 66%)曾多次因疾病相关入院。13例患者(62%,可信区间41 - 79%)超过50%的C反应蛋白(CRP)结果高于8 mg/L。精神合并症很常见,19例患者(59%,可信区间42 - 74%)存在精神合并症或治疗参与度低的情况。

结论

在这个队列中,我们强调了治疗参与度低、在有指征时不愿增加治疗剂量以及心理合并症可能是导致疾病控制不佳和胃肠道腺癌发生的因素。基于我们的数据,在预防IBD相关的胃肠道恶性肿瘤时,这些易于识别的临床护理因素不应被忽视。需要进一步研究来评估直接因果关系,但本研究支持将心理服务纳入IBD诊所。

相似文献

1
Gastrointestinal neoplasia in patients with inflammatory bowel disease: Opportunities to enhance preventative strategies.炎症性肠病患者的胃肠道肿瘤:加强预防策略的机遇
JGH Open. 2019 May 14;3(6):513-517. doi: 10.1002/jgh3.12193. eCollection 2019 Dec.
2
Poor engagement and adherence predict neoplasia in inflammatory bowel disease: a case-control study.较差的参与度和依从性可预测炎症性肠病中的肿瘤形成:一项病例对照研究。
Intern Med J. 2023 May;53(5):731-737. doi: 10.1111/imj.15760. Epub 2022 May 30.
3
Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom.炎症性肠病中低级别和高级别发育异常的管理:英国胃肠病学家的观点及当前实践
Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1317-24. doi: 10.1097/00042737-200512000-00009.
4
Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.炎症性肠病患者结直肠低级别异型增生后高级别瘤变的长期风险:一项全国性队列研究。
J Crohns Colitis. 2019 Dec 10;13(12):1485-1491. doi: 10.1093/ecco-jcc/jjz114.
5
Nearly a Third of High-Grade Dysplasia and Colorectal Cancer Is Undetected in Patients with Inflammatory Bowel Disease.近三分之一的炎症性肠病患者存在高级别发育异常和结直肠癌未被检测出。
Dig Dis Sci. 2017 Dec;62(12):3586-3593. doi: 10.1007/s10620-017-4652-5. Epub 2017 Jun 19.
6
Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease.他汀类药物暴露与炎症性肠病患者结直肠肿瘤发生率降低无关。
Gut Liver. 2019 Jan 15;13(1):54-61. doi: 10.5009/gnl18178.
7
Clinical implications of low grade dysplasia found during inflammatory bowel disease surveillance: a retrospective study comparing chromoendoscopy and white-light endoscopy.炎症性肠病监测中发现低级别上皮内瘤变的临床意义:比较 chromoendoscopy 和白光内镜的回顾性研究。
Endoscopy. 2017 Feb;49(2):161-168. doi: 10.1055/s-0042-119394. Epub 2016 Dec 12.
8
Non-conventional dysplasia in inflammatory bowel disease is more frequently associated with advanced neoplasia and aneuploidy than conventional dysplasia.非典型性异型增生在炎症性肠病中比典型性异型增生更常与高级别肿瘤和非整倍体相关。
Histopathology. 2021 May;78(6):814-830. doi: 10.1111/his.14298. Epub 2020 Dec 23.
9
Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease.先前的结直肠肿瘤与炎症性肠病患者的回肠贮袋肿瘤风险增加相关。
Gastroenterology. 2014 Jan;146(1):119-28.e1. doi: 10.1053/j.gastro.2013.09.047. Epub 2013 Sep 25.
10
High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease.原发性硬化性胆管炎合并炎症性肠病患者发生高级别结直肠肿瘤的风险较高。
Clin Gastroenterol Hepatol. 2018 Jul;16(7):1106-1113.e3. doi: 10.1016/j.cgh.2018.01.023. Epub 2018 Mar 15.

本文引用的文献

1
Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis.使用硫唑嘌呤可降低炎症性肠病相关结直肠肿瘤的风险:系统评价和荟萃分析。
J Crohns Colitis. 2018 Apr 27;12(5):546-558. doi: 10.1093/ecco-jcc/jjy006.
2
Advances in the Diagnosis and Management of Colonic Dysplasia in Patients With Inflammatory Bowel Disease.炎症性肠病患者结肠发育异常的诊断与管理进展
Gastroenterol Hepatol (N Y). 2017 Jun;13(6):357-362.
3
A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer.炎症性肠病相关结直肠癌的临床病理特征及生存结局的荟萃分析
Int J Colorectal Dis. 2017 Apr;32(4):443-451. doi: 10.1007/s00384-017-2754-3. Epub 2017 Jan 11.
4
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.医学治疗在降低结直肠癌风险及优化炎症性肠病监测方面的潜力。
Gastrointest Endosc Clin N Am. 2014 Jul;24(3):353-65. doi: 10.1016/j.giec.2014.03.008. Epub 2014 May 6.
5
Cause-specific mortality and 30-year relative survival of Crohn's disease and ulcerative colitis.炎症性肠病的病因特异性死亡率和 30 年相对生存率。
Inflamm Bowel Dis. 2013 Aug;19(9):1880-8. doi: 10.1097/MIB.0b013e31829080a8.
6
Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).炎症性肠病中的结直肠癌:第 3 届 ECCO 发病机制科学研讨会(I)的结果。
J Crohns Colitis. 2014 Jan;8(1):5-18. doi: 10.1016/j.crohns.2013.04.008. Epub 2013 May 9.
7
Psychotherapy for inflammatory bowel disease: a review and update.炎症性肠病的心理治疗:综述与更新。
J Crohns Colitis. 2013 Dec;7(12):935-49. doi: 10.1016/j.crohns.2013.02.004. Epub 2013 Mar 5.
8
Intestinal inflammation and cancer.肠道炎症与癌症。
Gastroenterology. 2011 May;140(6):1807-16. doi: 10.1053/j.gastro.2011.01.057.
9
The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study.炎症性肠病相关结直肠癌的发病风险有限:一项全国性巢式病例对照研究结果。
Am J Gastroenterol. 2011 Feb;106(2):319-28. doi: 10.1038/ajg.2010.428. Epub 2010 Nov 2.
10
Inflammation and colon cancer.炎症与结肠癌。
Gastroenterology. 2010 Jun;138(6):2101-2114.e5. doi: 10.1053/j.gastro.2010.01.058.